268 related articles for article (PubMed ID: 17725987)
1. Functional correction of CNS lesions in an MPS-IIIA mouse model by intracerebral AAV-mediated delivery of sulfamidase and SUMF1 genes.
Fraldi A; Hemsley K; Crawley A; Lombardi A; Lau A; Sutherland L; Auricchio A; Ballabio A; Hopwood JJ
Hum Mol Genet; 2007 Nov; 16(22):2693-702. PubMed ID: 17725987
[TBL] [Abstract][Full Text] [Related]
2. Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I/II trial.
Tardieu M; Zérah M; Husson B; de Bournonville S; Deiva K; Adamsbaum C; Vincent F; Hocquemiller M; Broissand C; Furlan V; Ballabio A; Fraldi A; Crystal RG; Baugnon T; Roujeau T; Heard JM; Danos O
Hum Gene Ther; 2014 Jun; 25(6):506-16. PubMed ID: 24524415
[TBL] [Abstract][Full Text] [Related]
3. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA.
Gray AL; O'Leary C; Liao A; Agúndez L; Youshani AS; Gleitz HF; Parker H; Taylor JT; Danos O; Hocquemiller M; Palomar N; Linden RM; Henckaerts E; Holley RJ; Bigger BW
Hum Gene Ther; 2019 Sep; 30(9):1052-1066. PubMed ID: 31020862
[TBL] [Abstract][Full Text] [Related]
4. A Preclinical Study Evaluating AAVrh10-Based Gene Therapy for Sanfilippo Syndrome.
Winner LK; Beard H; Hassiotis S; Lau AA; Luck AJ; Hopwood JJ; Hemsley KM
Hum Gene Ther; 2016 May; 27(5):363-75. PubMed ID: 26975339
[TBL] [Abstract][Full Text] [Related]
5. Overcoming Limitations Inherent in Sulfamidase to Improve Mucopolysaccharidosis IIIA Gene Therapy.
Chen Y; Zheng S; Tecedor L; Davidson BL
Mol Ther; 2018 Apr; 26(4):1118-1126. PubMed ID: 29503202
[TBL] [Abstract][Full Text] [Related]
6. Reduction in Brain Heparan Sulfate with Systemic Administration of an IgG Trojan Horse-Sulfamidase Fusion Protein in the Mucopolysaccharidosis Type IIIA Mouse.
Boado RJ; Lu JZ; Hui EK; Pardridge WM
Mol Pharm; 2018 Feb; 15(2):602-608. PubMed ID: 29251941
[TBL] [Abstract][Full Text] [Related]
7. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies.
Fraldi A; Biffi A; Lombardi A; Visigalli I; Pepe S; Settembre C; Nusco E; Auricchio A; Naldini L; Ballabio A; Cosma MP
Biochem J; 2007 Apr; 403(2):305-12. PubMed ID: 17206939
[TBL] [Abstract][Full Text] [Related]
8. Broad functional correction of molecular impairments by systemic delivery of scAAVrh74-hSGSH gene delivery in MPS IIIA mice.
Duncan FJ; Naughton BJ; Zaraspe K; Murrey DA; Meadows AS; Clark KR; Newsom DE; White P; Fu H; McCarty DM
Mol Ther; 2015 Apr; 23(4):638-47. PubMed ID: 25592334
[TBL] [Abstract][Full Text] [Related]
9. An Engineered
Douek AM; Amiri Khabooshan M; Henry J; Stamatis SA; Kreuder F; Ramm G; Änkö ML; Wlodkowic D; Kaslin J
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34073041
[TBL] [Abstract][Full Text] [Related]
10. Systemic scAAV9.U1a.hSGSH Delivery Corrects Brain Biochemistry in Mucopolysaccharidosis Type IIIA at Early and Later Stages of Disease.
Saville JT; Derrick-Roberts ALK; McIntyre C; Fuller M
Hum Gene Ther; 2021 Apr; 32(7-8):420-430. PubMed ID: 33339477
[TBL] [Abstract][Full Text] [Related]
11. Effect of cisternal sulfamidase delivery in MPS IIIA Huntaway dogs--a proof of principle study.
Hemsley KM; Norman EJ; Crawley AC; Auclair D; King B; Fuller M; Lang DL; Dean CJ; Jolly RD; Hopwood JJ
Mol Genet Metab; 2009 Dec; 98(4):383-92. PubMed ID: 19699666
[TBL] [Abstract][Full Text] [Related]
12. High and prolonged sulfamidase secretion by the liver of MPS-IIIA mice following hydrodynamic tail vein delivery of antibiotic-free pFAR4 plasmid vector.
Quiviger M; Arfi A; Mansard D; Delacotte L; Pastor M; Scherman D; Marie C
Gene Ther; 2014 Dec; 21(12):1001-7. PubMed ID: 25142140
[TBL] [Abstract][Full Text] [Related]
13. Neuronal-specific impairment of heparan sulfate degradation in Drosophila reveals pathogenic mechanisms for Mucopolysaccharidosis type IIIA.
Webber DL; Choo A; Hewson LJ; Trim PJ; Snel MF; Hopwood JJ; Richards RI; Hemsley KM; O'Keefe LV
Exp Neurol; 2018 May; 303():38-47. PubMed ID: 29408731
[TBL] [Abstract][Full Text] [Related]
14. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice.
Gustavsson S; Ohlin Sjöström E; Tjernberg A; Janson J; Westermark U; Andersson T; Makower Å; Arnelöf E; Andersson G; Svartengren J; Ekholm C; Svensson Gelius S
Mol Genet Metab Rep; 2019 Dec; 21():100510. PubMed ID: 31528541
[TBL] [Abstract][Full Text] [Related]
15. A novel conditional Sgsh knockout mouse model recapitulates phenotypic and neuropathic deficits of Sanfilippo syndrome.
Lau AA; King BM; Thorsen CL; Hassiotis S; Beard H; Trim PJ; Whyte LS; Tamang SJ; Duplock SK; Snel MF; Hopwood JJ; Hemsley KM
J Inherit Metab Dis; 2017 Sep; 40(5):715-724. PubMed ID: 28451919
[TBL] [Abstract][Full Text] [Related]
16. Genetic manipulation of murine embryonic stem cells with enhanced green fluorescence protein and sulfatase-modifying factor I genes.
Zhao G; Karageorgos L; Hutchinson RG; Hopwood JJ; Hemsley K
Cytotherapy; 2010 May; 12(3):400-7. PubMed ID: 20370351
[TBL] [Abstract][Full Text] [Related]
17. Lentiviral-mediated gene therapy for murine mucopolysaccharidosis type IIIA.
McIntyre C; Derrick Roberts AL; Ranieri E; Clements PR; Byers S; Anson DS
Mol Genet Metab; 2008 Apr; 93(4):411-8. PubMed ID: 18248829
[TBL] [Abstract][Full Text] [Related]
18. Intracerebroventricular dosing of N-sulfoglucosamine sulfohydrolase in mucopolysaccharidosis IIIA mice reduces markers of brain lysosomal dysfunction.
Magat J; Jones S; Baridon B; Agrawal V; Wong H; Giaramita A; Mangini L; Handyside B; Vitelli C; Parker M; Yeung N; Zhou Y; Pungor E; Slabodkin I; Gorostiza O; Aguilera A; Lo MJ; Alcozie S; Christianson TM; Tiger PMN; Vincelette J; Fong S; Gil G; Hague C; Lawrence R; Wendt DJ; Lebowitz JH; Bunting S; Bullens S; Crawford BE; Roy SM; Woloszynek JC
J Biol Chem; 2022 Dec; 298(12):102625. PubMed ID: 36306823
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of a combined intracerebral and systemic gene delivery approach for the treatment of a severe lysosomal storage disorder.
Spampanato C; De Leonibus E; Dama P; Gargiulo A; Fraldi A; Sorrentino NC; Russo F; Nusco E; Auricchio A; Surace EM; Ballabio A
Mol Ther; 2011 May; 19(5):860-9. PubMed ID: 21326216
[TBL] [Abstract][Full Text] [Related]
20. Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.
Ruzo A; Garcia M; Ribera A; Villacampa P; Haurigot V; Marcó S; Ayuso E; Anguela XM; Roca C; Agudo J; Ramos D; Ruberte J; Bosch F
Mol Ther; 2012 Feb; 20(2):254-66. PubMed ID: 22008915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
